Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbhfiledCriticalImmatics Biotechnologies Gmbh
Publication of AR111370A1publicationCriticalpatent/AR111370A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Péptidos, proteínas, ácido nucleicos y células de utilidad en métodos inmunoterapéuticos. En particular, la presente se relaciona con inmunoterapias contra el cáncer. Se relaciona además con epitopes de péptidos de células T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que pueden servir, por ejemplo, como ingredientes farmacéuticos activos en composiciones de vacunas que estimulan respuestas inmunológicas anti-tumorales o para estimular células T ex vivo y transferirlas a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o péptidos semejantes, también pueden ser blancos de anticuerpos, receptores de células T solubles y otras moléculas de unión.Peptides, proteins, nucleic acids and cells useful in immunotherapeutic methods. In particular, this is related to cancer immunotherapies. It also relates to epitopes of T-cell peptides associated with tumors, alone or in combination with other peptides associated with tumors that can serve, for example, as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses or to stimulate cells. T ex vivo and transfer them to patients. Peptides bound to major histocompatibility complex (MHC) molecules, or similar peptides, can also be targets of antibodies, soluble T cell receptors and other binding molecules.
ARP180100892A2017-04-102018-04-10
PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPIES AGAINST LEUKEMIA AND OTHER CANCER
AR111370A1
(en)